{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AQST/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T11:29:34.177Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2837,"canonical_name":"Aquestive Therapeutics, Inc.","cik":"0001398733","uei":null,"lei":null,"duns":null,"ticker":"AQST"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":57},"count":57,"timeline":[{"ts":"2026-10-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-10-14","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000056","accession_number":"0001398733-26-000056","importance":35},{"ts":"2026-10-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Aquestive Therapeutics, Inc. — 2026-10-07","url_slug":"/sec/cik-0001398733/schedule-13g/0000897423-26-000125","accession_number":"0000897423-26-000125","importance":55},{"ts":"2026-09-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-09-29","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000052","accession_number":"0001398733-26-000052","importance":35},{"ts":"2026-09-25","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-09-25","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000048","accession_number":"0001398733-26-000048","importance":35},{"ts":"2026-09-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-09-17","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000044","accession_number":"0001398733-26-000044","importance":35},{"ts":"2026-09-16","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-09-16","url_slug":"/sec/cik-0001398733/4/0001214659-26-011731","accession_number":"0001214659-26-011731","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-09-15","url_slug":"/sec/cik-0001398733/144/0001950047-26-009530","accession_number":"0001950047-26-009530","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-09-11","url_slug":"/sec/cik-0001398733/4/0001214659-26-011596","accession_number":"0001214659-26-011596","importance":30},{"ts":"2026-09-10","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001398733/4/0001214659-26-011541","accession_number":"0001214659-26-011541","importance":30},{"ts":"2026-09-09","kind":"sec.insider.s","reporter":"Korczynski Sherry","title":"Chief Commercial Officer","shares":8750,"price_per_share":5.22,"usd_value":45675,"security_title":"Common Stock","importance":35.045675},{"ts":"2026-09-09","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001398733/144/0001950047-26-009243","accession_number":"0001950047-26-009243","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001398733/4/0001214659-26-011539","accession_number":"0001214659-26-011539","importance":30},{"ts":"2026-09-09","kind":"sec.insider.m","reporter":"Korczynski Sherry","title":"Chief Commercial Officer","shares":8750,"price_per_share":2.65,"usd_value":23188,"security_title":"Common Stock","importance":15.0231875},{"ts":"2026-09-08","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-09-08","url_slug":"/sec/cik-0001398733/4/0001214659-26-011475","accession_number":"0001214659-26-011475","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-08-18","url_slug":"/sec/cik-0001398733/4/0001214659-26-010516","accession_number":"0001214659-26-010516","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001398733/144/0001950047-26-008250","accession_number":"0001950047-26-008250","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001398733/4/0001214659-26-010474","accession_number":"0001214659-26-010474","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Aquestive Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001398733/10-q/0001398733-26-000042","accession_number":"0001398733-26-000042","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000041","accession_number":"0001398733-26-000041","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-08-10","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000035","accession_number":"0001398733-26-000035","importance":35},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Aquestive Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001398733/schedule-13g-a/0002012383-26-002183","accession_number":"0002012383-26-002183","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0001398733/4/0001214659-26-008663","accession_number":"0001214659-26-008663","importance":30},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Barber Daniel","title":"President and CEO","shares":20369,"price_per_share":4.0016,"usd_value":81509,"security_title":"Common Stock","importance":35.0815085904},{"ts":"2026-07-15","kind":"sec.form144","reporter":"Daniel Barber","title":"Officer","shares":25000,"usd_value":101000,"security_title":"Common","approx_sale_date":"2026-07-15","accession_number":"0001950047-26-007131","importance":40.0202},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Barber Daniel","title":"President and CEO","shares":4631,"price_per_share":4.0344,"usd_value":18683,"security_title":"Common Stock","importance":35.0186833064},{"ts":"2026-07-15","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-07-15","url_slug":"/sec/cik-0001398733/144/0001950047-26-007131","accession_number":"0001950047-26-007131","importance":30},{"ts":"2026-07-09","kind":"sec.filing","form_type":"424B3","title":"424B3 — Aquestive Therapeutics, Inc. — 2026-07-09","url_slug":"/sec/cik-0001398733/424b3/0001140361-26-028114","accession_number":"0001140361-26-028114","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Aquestive Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001398733/effect/9999999995-26-002228","accession_number":"9999999995-26-002228","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"S-3","title":"S-3 — Aquestive Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001398733/s-3/0001140361-26-026568","accession_number":"0001140361-26-026568","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001398733/4/0001214659-26-007677","accession_number":"0001214659-26-007677","importance":30},{"ts":"2026-06-23","kind":"sec.form144","reporter":"JULIE KROP","title":"Director","shares":25000,"usd_value":118000,"security_title":"Common","approx_sale_date":"2026-06-23","accession_number":"0001950047-26-006421","importance":40.0236},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Krop Julie","title":"","shares":25000,"price_per_share":5.0157,"usd_value":125393,"security_title":"Common Stock","importance":35.1253925},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001398733/144/0001950047-26-006421","accession_number":"0001950047-26-006421","importance":30},{"ts":"2026-06-23","kind":"sec.insider.m","reporter":"Krop Julie","title":"","shares":25000,"price_per_share":0.7132,"usd_value":17830,"security_title":"Common Stock","importance":15.01783},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001398733/4/0001214659-26-007511","accession_number":"0001214659-26-007511","importance":30},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Daniel Barber","title":"Officer","shares":25000,"usd_value":104250,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006103","importance":40.02085},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Barber Daniel","title":"President and CEO","shares":25000,"price_per_share":4.1604,"usd_value":104010,"security_title":"Common Stock","importance":35.10401},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-06-15","url_slug":"/sec/cik-0001398733/144/0001950047-26-006103","accession_number":"0001950047-26-006103","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001398733/4/0001214659-26-007394","accession_number":"0001214659-26-007394","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001398733/4/0001214659-26-007396","accession_number":"0001214659-26-007396","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001398733/4/0001214659-26-007397","accession_number":"0001214659-26-007397","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001398733/4/0001214659-26-007398","accession_number":"0001214659-26-007398","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000033","accession_number":"0001398733-26-000033","importance":35},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-06-09","url_slug":"/sec/cik-0001398733/4/0001214659-26-007262","accession_number":"0001214659-26-007262","importance":30},{"ts":"2026-06-08","kind":"sec.insider.f","reporter":"Korczynski Sherry","title":"Chief Commercial Officer","shares":2714,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-05-19","url_slug":"/sec/cik-0001398733/4/0001214659-26-006554","accession_number":"0001214659-26-006554","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001398733/4/0001214659-26-006527","accession_number":"0001214659-26-006527","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001398733/4/0001214659-26-006532","accession_number":"0001214659-26-006532","importance":30},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Zalewski Thomas A.","title":"Chief Legal Officer","shares":100000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Daniel Barber","title":"Officer","shares":8257,"usd_value":39056,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001950047-26-004630","importance":40.007811122},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Barber Daniel","title":"President and CEO","shares":8257,"price_per_share":4.2889,"usd_value":35413,"security_title":"Common Stock","importance":35.0354134473},{"ts":"2026-05-15","kind":"sec.filing","form_type":"144","title":"144 — Aquestive Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001398733/144/0001950047-26-004630","accession_number":"0001950047-26-004630","importance":30},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Cioffi Melina","title":"SVP, Regulatory Affairs","shares":1667,"price_per_share":4.17,"usd_value":6951,"security_title":"Common Stock","importance":15.00695139},{"ts":"2026-05-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Aquestive Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001398733/10-q/0001398733-26-000030","accession_number":"0001398733-26-000030","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Aquestive Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001398733/8-k/0001398733-26-000029","accession_number":"0001398733-26-000029","importance":35},{"ts":"2026-05-11","kind":"sec.filing","form_type":"4","title":"4 — Aquestive Therapeutics, Inc. — 2026-05-11","url_slug":"/sec/cik-0001398733/4/0001214659-26-005932","accession_number":"0001214659-26-005932","importance":30},{"ts":"2026-05-07","kind":"sec.insider.f","reporter":"BRAENDER LORI J","title":"Corporate Secretary","shares":135690,"price_per_share":4.23,"usd_value":573969,"security_title":"Common Stock","importance":15.5739687}]}